Yiteng medicine is authorized to sell the new GlaxoSmithKline breast cancer drug taliza
-
Last Update: 2020-04-03
-
Source: Internet
-
Author: User
Search more information of high quality chemicals, good prices and reliable suppliers, visit
www.echemi.com
Yiteng Pharmaceutical Co., Ltd., a professional pharmaceutical company, announced on April 9 that it has obtained the exclusive right to distribute thalassar, a new GlaxoSmithKline drug for the treatment of advanced or metastatic breast cancer, in China Ni Xin, chairman and CEO of Yiteng Pharmaceutical Co., Ltd., said that this is the first time that Chinese pharmaceutical companies have participated in the listing of global patented anti-tumor drugs in China GlaxoSmithKline's tykerb (generic name: rapatinib xylenesulfonate tablets, trade name: rapatinib) is an innovative drug for the treatment of cancer, which has been listed in more than 100 countries and regions, and recently approved by the State Food and Drug Administration (SFDA) for the treatment of advanced or metastatic breast cancer According to the cooperation agreement between Yiteng pharmaceutical and GlaxoSmithKline, Yiteng pharmaceutical has the exclusive right to import, market, promote, distribute and sell taliza in mainland China.
This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only.
This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of
the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed
description of the concern or complaint, to
service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content
will be removed immediately.
